No profile data available.
Veraxa Biotech AG (VRXA) is a listed company, based in Heidelberg, Germany.
It reported revenue of $23,426 for fiscal year 2025, and net income of -$66.61 million. Its market capitalization was $178.17 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Veraxa Biotech reported $23,426 in revenue for fiscal year 2025.
$178.17 million as of October 9, 2026.